These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 37516849)

  • 41. TPD7 inhibits the growth of cutaneous T cell lymphoma H9 cell through regulating IL-2R signalling pathway.
    Zhu M; Yang L; Shi X; Gong Z; Yu R; Zhang D; Zhang Y; Ma W
    J Cell Mol Med; 2020 Jan; 24(1):984-995. PubMed ID: 31742861
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune checkpoint blockade combined with IL-6 and TGF-β inhibition improves the therapeutic outcome of mRNA-based immunotherapy.
    Bialkowski L; Van der Jeught K; Bevers S; Tjok Joe P; Renmans D; Heirman C; Aerts JL; Thielemans K
    Int J Cancer; 2018 Aug; 143(3):686-698. PubMed ID: 29464699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets.
    Ray SK; Mukherjee S
    Curr Drug Targets; 2022; 23(5):471-485. PubMed ID: 35021970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.
    Antony PA; Paulos CM; Ahmadzadeh M; Akpinarli A; Palmer DC; Sato N; Kaiser A; Hinrichs CS; Klebanoff CA; Tagaya Y; Restifo NP
    J Immunol; 2006 May; 176(9):5255-66. PubMed ID: 16621991
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.
    Krieg C; Létourneau S; Pantaleo G; Boyman O
    Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11906-11. PubMed ID: 20547866
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy.
    Li T; Qiao T
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):117-125. PubMed ID: 36183998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Blocking IL-2 Signal In Vivo with an IL-2 Antagonist Reduces Tumor Growth through the Control of Regulatory T Cells.
    Carmenate T; Ortíz Y; Enamorado M; García-Martínez K; Avellanet J; Moreno E; Graça L; León K
    J Immunol; 2018 May; 200(10):3475-3484. PubMed ID: 29618524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Altered gene transcription after burn injury results in depressed T-lymphocyte activation.
    Horgan AF; Mendez MV; O'Riordain DS; Holzheimer RG; Mannick JA; Rodrick ML
    Ann Surg; 1994 Sep; 220(3):342-51; discussion 351-2. PubMed ID: 8092900
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging organoid-immune co-culture models for cancer research: from oncoimmunology to personalized immunotherapies.
    Magré L; Verstegen MMA; Buschow S; van der Laan LJW; Peppelenbosch M; Desai J
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220953
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The emerging role of miRNA in the perturbation of tumor immune microenvironment in chemoresistance: Therapeutic implications.
    Mondal P; Kaur B; Natesh J; Meeran SM
    Semin Cell Dev Biol; 2022 Apr; 124():99-113. PubMed ID: 33865701
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting IL-17alpha to promote anti-PD-1 therapy effect by screening the tumor immune microenvironment in a mouse oral carcinogenesis model.
    Wang S; Yu X; Li F; Fan H; Zhao E; Hu Z
    Cancer Biomark; 2021; 31(4):339-350. PubMed ID: 33896829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy.
    Tendler CL; Greenberg SJ; Blattner WA; Manns A; Murphy E; Fleisher T; Hanchard B; Morgan O; Burton JD; Nelson DL
    Proc Natl Acad Sci U S A; 1990 Jul; 87(13):5218-22. PubMed ID: 2367534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New Molecular and Cellular Mechanisms of Tolerance: Tolerogenic Actions of IL-2.
    Pérol L; Piaggio E
    Methods Mol Biol; 2016; 1371():11-28. PubMed ID: 26530792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advancements in osteosarcoma management: integrating immune microenvironment insights with immunotherapeutic strategies.
    Liang H; Cui M; Tu J; Chen X
    Front Cell Dev Biol; 2024; 12():1394339. PubMed ID: 38915446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
    Wang Y; Zhang H; He YW
    Front Immunol; 2019; 10():1574. PubMed ID: 31379815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of different targeting agents in the photolysis of interleukin-2 receptor bearing cells.
    Linares R; Pacheco JR; Good TA
    J Photochem Photobiol B; 2004 Dec; 77(1-3):17-26. PubMed ID: 15542358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor.
    Damoiseaux J
    Clin Immunol; 2020 Sep; 218():108515. PubMed ID: 32619646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting human IL-2 receptors for diagnosis and therapy.
    Nelson DL; Kurman CC
    Proc Soc Exp Biol Med; 1994 Jul; 206(3):309-11. PubMed ID: 8016170
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
    Paietta E; Nelson DL; Andersen J; Dutcher JP; Wiernik PH
    Med Oncol; 1995 Jun; 12(2):121-4. PubMed ID: 8535662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.